Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics, Inc. (GANX)
NASDAQ:GANX
GANX Stock Chart & Stats
$1.74
-$0.01(-0.44%)
At close: 4:00 PM EST
$1.74
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.41 - $4.34
Previous CloseN/A
Volume74.47K
Average Volume (3M)889.97K
Market Cap
$66.92M
Enterprise Value$60.99M
Total Cash (Recent Filing)$8.81M
Total Debt (Recent Filing)$180.94K
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Mar 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding38,462,086
10 Day Avg. Volume529,181
30 Day Avg. Volume889,971
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)6.73
Price to Sales (P/S)0.00
P/FCF Ratio-2.62
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.22
Enterprise Value/Ebitda-3.50
Forecast
1Y Price Target
$7.50Price Target Upside331.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker Target EngagementReduction of glucosylsphingosine in cerebrospinal fluid demonstrates that GT-02287 engages its intended brain target, validating the mechanism that supports potential disease‑modifying effects.
Progression To Phase 2Completion of an investigational new drug filing enabling a Phase 2 trial positions the program to advance from exploratory testing to more definitive clinical evaluation.
Safety And Patient RetentionFavorable tolerability and full enrollment into the long‑term extension indicate strong patient retention and a manageable safety profile for extended dosing.
Bears Say
Share Volatility And Funding RiskPronounced share price swings around the data release and commentary on expectations of a capital raise point to equity volatility and the potential for future dilution from financing needs.
Study Design And Size LimitationsOpen‑label design and small sample size of the Phase 1b study make the findings preliminary and necessitate larger, randomized trials for reliable confirmation.
Uncertain Clinical Benefit From BiomarkersBiomarker improvements have not been established as translating into meaningful patient benefit, leaving uncertainty about whether observed biochemical changes will slow clinical decline.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics, Inc.’s price range in the past 12 months?
Gain Therapeutics, Inc. lowest stock price was $1.41 and its highest was $4.34 in the past 12 months.
What is Gain Therapeutics, Inc.’s market cap?
Gain Therapeutics, Inc.’s market cap is $66.92M.
When is Gain Therapeutics, Inc.’s upcoming earnings report date?
Gain Therapeutics, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 33 days.
How were Gain Therapeutics, Inc.’s earnings last quarter?
Gain Therapeutics, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.161 by $0.011.
Is Gain Therapeutics, Inc. overvalued?
According to Wall Street analysts Gain Therapeutics, Inc.’s price is currently Undervalued.
Does Gain Therapeutics, Inc. pay dividends?
Gain Therapeutics, Inc. does not currently pay dividends.
What is Gain Therapeutics, Inc.’s EPS estimate?
Gain Therapeutics, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Gain Therapeutics, Inc. have?
Gain Therapeutics, Inc. has 38,462,086 shares outstanding.
What happened to Gain Therapeutics, Inc.’s price movement after its last earnings report?
Gain Therapeutics, Inc. reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.161. Following the earnings report the stock price went up 10.075%.
Which hedge fund is a major shareholder of Gain Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gain Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (331.03% Upside)
$7.50 (331.03% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 12.2%
Last 30 Days ▼ 12.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.80%
12-Months-Change
Fundamentals
Return on Equity
-261.72%
Trailing 12-Months
Asset Growth
-23.63%
Trailing 12-Months
Company Description
Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$7.50
▲(331.03% Upside)
Technical Analysis
Plus Therapeutics
―
ABVC BioPharma
―
PMV Pharmaceuticals
―
Prelude Therapeutics
―
Immix Biopharma
―
Ownership Overview
3.33%
Insiders
1.66% Mutual Funds
0.10% Other Institutional Investors
93.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---